{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:00:39Z","timestamp":1792299639635,"version":"4.4.0"},"reference-count":85,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cent Nerv Syst Dis"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute ischemic stroke (AIS) is a leading cause of death and disability. Glucagon-like peptide-1 receptor agonists (GLP-1RA) reduce atherosclerotic events in type 2 diabetes and obesity, and meta-analyses of cardiovascular outcome trials (CVOTs) suggest a modest reduction in incident stroke. Their safety and efficacy within acute AIS pathways remain uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a narrative review by searching MEDLINE (PubMed), Cochrane CENTRAL, and ClinicalTrials.gov for studies through January 2026. We included in vitro and animal stroke models, observational studies, randomized controlled trials, and meta-analyses reporting AIS-related outcomes or stroke prevention endpoints with GLP-1RA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Experimental models commonly show reduced infarct volume and improved neurological outcomes, with proposed mechanisms including attenuation of excitotoxicity, apoptosis, oxidative stress, neuroinflammation, and blood-brain barrier disruption, alongside signals of angiogenesis and neurogenesis. Translation is limited by heterogeneity of agents, timing, dosing, and routes, and by uncertainty over direct central nervous system versus systemic mediation. CVOTs and meta-analyses support long-term stroke risk reduction, whereas observational studies and small AIS trials mainly inform feasibility, metabolic control, and safety, with efficacy unproven. Ongoing stroke-dedicated trials should define patient selection, exposure\u2013response relationships, and interactions with thrombolysis or thrombectomy, while prospectively incorporating imaging and biomarker endpoints to test mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Current evidence does not support routine GLP-1RA use as an acute neuroprotective therapy in AIS in humans. At present, GLP-1RA should be considered primarily for secondary prevention in patients with established indications, pending dedicated stroke trials clarifying acute safety, optimal timing\/dosing, interactions with reperfusion therapies, and functional endpoints.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11795735261444425","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:02:52Z","timestamp":1776398572000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["GLP-1 Receptor Agonists in Acute Ischemic Stroke and Secondary Stroke Prevention: A Narrative Review of Preclinical and Clinical Evidence"],"prefix":"10.1177","volume":"18","author":[{"given":"Valentini","family":"Samanidou","sequence":"first","affiliation":[{"name":"School of Health Sciences, University of Ioannina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Tsamis","sequence":"additional","affiliation":[{"name":"University of Ioannina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandr","family":"Ceasovschih","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theocharis","family":"Koufakis","sequence":"additional","affiliation":[{"name":"Aristotle University of Thessaloniki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Patoulias","sequence":"additional","affiliation":[{"name":"Aristotle University of Thessaloniki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos C.","family":"Rizos","sequence":"additional","affiliation":[{"name":"University of Ioannina"},{"name":"University of Ioannina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfredi","family":"Rizzo","sequence":"additional","affiliation":[{"name":"University of Palermo"},{"name":"Internal Medicine Department, College of Medical Sciences, Ras Al Khaimah Medical and Health Sciences University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haralampos","family":"Milionis","sequence":"additional","affiliation":[{"name":"School of Health Sciences, University of Ioannina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5940-6895","authenticated-orcid":false,"given":"Fotios","family":"Barkas","sequence":"additional","affiliation":[{"name":"School of Health Sciences, University of Ioannina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/17474930241308142"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00277-6"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00369-7"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.2337\/db16-0766"},{"issue":"6","key":"e_1_3_4_6_2","first-page":"618","article-title":"The influence of diabetes mellitus and hyperglycaemia on stroke incidence and outcome","volume":"9","author":"Baird TA","year":"2002","unstructured":"Baird TA, Parsons MW, Barber PA, et al. The influence of diabetes mellitus and hyperglycaemia on stroke incidence and outcome. J Clin Neurosci Off J Neurosurg Soc Australas. 2002;9(6):618-626.","journal-title":"J Clin Neurosci Off J Neurosurg Soc Australas"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403347"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306963"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S009"},{"key":"e_1_3_4_10_2","first-page":"174749302412539","article-title":"Glucagon-like peptide-1 receptor agonists and stroke: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"21","author":"Adamou A","year":"2024","unstructured":"Adamou A, Barkas F, Milionis H, et al. Glucagon-like peptide-1 receptor agonists and stroke: A systematic review and meta-analysis of cardiovascular outcome trials. Int J Stroke. 2024;21:17474930241253988.","journal-title":"Int J Stroke"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-014-9285-9"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70125-6"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.2165\/11635890-000000000-00000"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-13-0221"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2022122"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2011.51"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms141121513"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0103114"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2015.01.014"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/WNR.0000000000000490"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2017.01.045"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2018.05.045"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107748"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.29204"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2019.00585"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15524"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.4103\/bc.bc_38_24"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509225"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612917"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32261-X"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901118"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108269"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501006"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm919"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.10611"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(03)00160-3"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.300.3.958"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2010.10.008"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2012.01971.x"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2003.02073.x"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0806720106"},{"issue":"10","key":"e_1_3_4_46_2","first-page":"473","article-title":"Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats","volume":"122","author":"Darsalia V","year":"2012","unstructured":"Darsalia V, Mansouri S, Orts\u00e4ter H, et al. Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats. Clin Sci Lond Engl 1979. 2012;122(10):473-483.","journal-title":"Clin Sci Lond Engl 1979"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.116.012934"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2012.118"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2015.126"},{"key":"e_1_3_4_50_2","first-page":"82","article-title":"Pro-GLP-1, a Pro-drug of GLP-1, is neuroprotective in cerebral ischemia","volume":"70","author":"Zhang H","year":"2015","unstructured":"Zhang H, Meng J, Li X, et al. Pro-GLP-1, a Pro-drug of GLP-1, is neuroprotective in cerebral ischemia. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2015;70:82-91.","journal-title":"Eur J Pharm Sci Off J Eur Fed Pharm Sci"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148827"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2016.11.010"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1177\/0271678X20952011"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2014.09.064"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep26859"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-020-01497-9"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3094504"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0661-0"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.12.015"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2013.04.010"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2013.11.006"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.037481"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12974"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-022-02811-9"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2009.12.023"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2014.08.014"},{"issue":"1","key":"e_1_3_4_67_2","first-page":"e12984_198","article-title":"Abstract 198: Association of GLP\u20101 Receptor Agonist Use with Clinical Outcomes in Diabetic Patients Hospitalized for Ischemic Stroke","volume":"4","author":"Iourinets J","year":"2025","unstructured":"Iourinets J, Viswanath V, Jhaveri A, et al. Abstract 198: Association of GLP\u20101 Receptor Agonist Use with Clinical Outcomes in Diabetic Patients Hospitalized for Ischemic Stroke. Stroke Vasc Interv Neurol. 2025;4(Suppl 1):e12984_198.","journal-title":"Stroke Vasc Interv Neurol"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13470-w"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwag002"},{"issue":"9","key":"e_1_3_4_70_2","first-page":"1645","article-title":"Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial","volume":"33","author":"Lam CSP","year":"2025","unstructured":"Lam CSP, Rodriguez A, Aminian A, et al. Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial. Obesity. 2025 Sept. 2025;33(9):1645-1656.","journal-title":"Obesity. 2025 Sept"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30423-1"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.121.037775"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13905"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16476"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijs.12073"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13166"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.123.044568"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2025.5684"},{"key":"e_1_3_4_79_2","unstructured":"Study Details | Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke | ClinicalTrials.gov. Available from. https:\/\/clinicaltrials.gov\/study\/NCT05630586"},{"key":"e_1_3_4_80_2","unstructured":"Study Details | Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies | ClinicalTrials.gov. Available from. https:\/\/clinicaltrials.gov\/study\/NCT05920889"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4330-3"},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2013.12.015"},{"key":"e_1_3_4_83_2","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S375559"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000006810"},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00464-024-11263-2"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-021-01741-5"}],"container-title":["Journal of Central Nervous System Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795735261444425","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11795735261444425","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795735261444425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:59:35Z","timestamp":1781265575000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11795735261444425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":85,"alternative-id":["10.1177\/11795735261444425"],"URL":"https:\/\/doi.org\/10.1177\/11795735261444425","relation":{},"ISSN":["1179-5735","1179-5735"],"issn-type":[{"value":"1179-5735","type":"print"},{"value":"1179-5735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"article-number":"11795735261444425"}}